When leukaemia strikes an older person, it is in part due to the ageing of his or her haematopoietic stem cells (HSCs). These immature cells can develop into all types of blood cells, including white blood cells, red blood cells and platelets. As such, researchers have focused on rejuvenating HSCs as a way to treat leukaemia.

A new study released in Stem Cells adds much to that level of knowledge by showing that the youthful function of rejuvenated HSCs upon transplantation depends in part on a young bone marrow "niche," which is the microenvironment surrounding stem cells that interacts with them to regulate their fate.

"The information revealed by our study tells us that the influence of this niche needs to be considered in approaches to rejuvenate old HSCs for treating ageing-associated leukaemia or immune remodelling," said Hartmut Geiger, Ph.D, senior author of the study, conducted by researchers at Ulm University (Germany) and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Old HSCs exhibit a reduced reconstitution potential and other negative aspects such as altered gene expression profiles and an increase in apolar distribution of proteins.

Polarity is believed to be particularly important to fate decisions on stem cell division and for maintaining an HSC's interaction with its niche. Consequently, a failure to establish or regulate stem cell polarity might result in disease or tissue deterioration. Ageing of HSCs might even affect lifespan.

Researchers already knew that increased activity of a protein called Cdc42, which controls cell division, leads to HSC ageing, and that when old HSCs are treated ex vivo with CASIN, an inhibitor of Cdc42 activity, they stay rejuvenated upon transplantation into young recipients.

The aim of this latest study was to learn what happens to these rejuvenated HSCs when they are transplanted into an aged niche.

To find out, Dr. Geiger and his team transplanted rejuvenated aged HSCs into three groups of mice: young (8 to 10 weeks old), old (19 to 24 months old) and young cytokine osteopontin (OPN) knockout mice (8 to 12 weeks old).

The team had recently demonstrated that a decrease in the level of secreted OPN in the aged bone marrow niche confers hallmarks of ageing on young HSCs, and also that secreted OPN regulates HSC polarity.

Old HSC and rejuvenated old HSCs were therefore transplanted into the OPN knockout recipients to test whether a lack of this protein in the niche affects the function of old rejuvenated HSCs.

The results were then analysed for up to 23 weeks after transplantation.

"They showed us that an aged niche restrains the function of ex vivo rejuvenated HSCs, which is at least in part linked to a low level of OPN found in aged niches," Dr. Geiger reported.

"This tells us that in order to sustain the function of rejuvenated aged HSCs, we will likely need to address the influence of an aged niche on rejuvenated HSCs."

Dr. Jan Nolta, Editor-in-Chief of Stem Cells, said, "this study is an elegant demonstration of the molecular mechanisms by which the marrow microenvironment controls cellular ageing of haematopoietic stem cells. This new information will be extremely useful in the fields of transplantation and treatment of leukaemia and other disorders of the blood-forming system."

Source: AlphaMed Press

Image Source: AlphaMed Press